scholarly journals COVID-19 and Tinnitus

2020 ◽  
pp. 014556132097484
Author(s):  
Pramod Chirakkal ◽  
Amira Nasser Al Hail ◽  
Nasfareen Zada ◽  
Deepak S. Vijayakumar
Keyword(s):  
Skeletal Muscle ◽  
Central Nervous System ◽  
Nervous System ◽  
Hearing Loss ◽  
Case Report ◽  
Severe Acute Respiratory Syndrome ◽  
Social Isolation ◽  
Health Concerns ◽  
New Finding ◽  
Novel Coronavirus

Coronavirus disease 2019 (COVID-19) is an infectious respiratory disease caused by the severe acute respiratory syndrome coronavirus 2, brings with it a plethora of health concerns. Although most people have mild symptoms, which are respiratory in nature, some experience neurological symptoms, central nervous system manifestations, peripheral nervous manifestations, and skeletal muscle manifestations. But the damaging impact of COVID-19 virus on the hearing organs in the inner ear is a new finding yet to be explored. Currently, there is little evidence published connecting novel coronavirus and tinnitus directly. But according to the American Tinnitus Association, preexisting behavioral conditions make it more likely for patients to experience tinnitus due to the stress and depression associated with social isolation and infection avoidance. Hearing loss and Tinnitus is a common pathology seen in otolaryngology and there are numerous papers in literature describing its associations with other infections. However, this is the first reported case of hearing loss and tinnitus in a COVID-19 patient, in the State of Qatar, and this case report strives to contribute to the ocean of literature highlighting the need for otorhinolaryngologists to be aware of its correlation with COVID-19 virus.

scholarly journals COVID-19 induced encephalopathy – a Case Report

2020 ◽  
Author(s):  
Ramy Abdelnaby ◽  
Mohamed Elsayed ◽  
Francis Abele-Haupts ◽  
Mehmet E. Barkin ◽  
Markus A. Rudek ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Case Report ◽  
Severe Acute Respiratory Syndrome ◽  
Global Health ◽  
Health Problem ◽  
Clinical Presentation ◽  
Silent Period ◽  
Global Health Problem

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also called coronavirus disease 2019 (COVID-19), first appeared in December 2019 in Wuhan, China. It has rapidly spread to multiple countries and has become a global health problem. The effects of COVID-19 on the CNS (Central Nervous System) are reported in low but increasing numbers. We report a case of COVID-19-induced encephalopathy with a biphasic clinical presentation only after a neurologically silent period.

COVID-19, the Brain, and the Future: Is Infection by the Novel Coronavirus a Harbinger of Neurodegeneration?

2021 ◽  
Vol 21 ◽  
Author(s):  
Adejoke Onaolapo ◽  
Olakunle Onaolapo
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Severe Acute Respiratory Syndrome ◽  
Neurodegenerative Diseases ◽  
Central Nervous System Involvement ◽  
The Novel ◽  
Novel Coronavirus ◽  
The Impact ◽  
The Brain

: The possible impact of viral infections on the development or pathogenesis of neurodegenerative disorders remains largely unknown. However, there have been reports associating the influenza virus pandemic and long-term infection with the Japanese encephalitis virus with the development of post-encephalitic Parkinsonism or von Economo encephalitis. In the last one year plus, there has been a worldwide pandemic arising from infection with the novel coronavirus or severe acute respiratory syndrome coronavirus (SARS-CoV)-2 which causes a severe acute respiratory syndrome that has become associated with central nervous system symptoms or complications. Its possible central nervous system involvement is in line with emerging scientific evidence which shows that the human respiratory coronaviruses can enter the brain, infect neural cells, persist in the brain, and cause activation of myelin-reactive T cells. Currently, there is a dearth of scientific information on the acute or possible long-term impact of infection with SARS-CoV-2 on the development of dementias and/or neurodegenerative diseases. This is not unrelated to the fact that the virus is ‘new’, and its effects on humans are still being studied. This narrative review examines extant literature for the impact of corona virus infections on the brain; as it considers the possibility that coronavirus disease 2019 (COVID-19) could increase the risk for the development of neurodegenerative diseases or hasten their progression.

scholarly journals Reversible lesion of the corpus callosum associated with COVID-19: A case report

2021 ◽  
Vol 26 (4) ◽  
pp. 821-824
Author(s):  
Yagmur Inalkac Gemici ◽  
Irem Tasci
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Ischemic Stroke ◽  
Case Report ◽  
Severe Acute Respiratory Syndrome ◽  
Rare Case ◽  
Splenial Lesion ◽  
Reversible Lesion ◽  
The Central Nervous System ◽  
Reversible Splenial Lesion Syndrome

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may affect the central nervous system and peripheral nervous system. Major central nervous system manifestations of SARS-CoV-2 infection include seizures, meningoencephalitis, ischemic stroke, anosmia, and hypogeusia. The reversible splenial lesion syndrome was first described in 2004. Although reversible splenial lesion syndrome was initially recognized as a benign phenomenon, a second type of reversible splenial lesion syndrome was identified in later years, which has a poorer prognosis and potentially serious sequela. Reversible splenial lesion syndrome can be caused by numerous etiologies including viruses. In this report, we present a rare case of COVID-19 with reversible splenial lesion, who presented with ataxia and dizziness.

Acute psychotic symptoms caused by overlapping central nervous system pathologies: a case report

2020 ◽  
pp. 376-379
Author(s):  
Gorkem Ugurlu ◽  
Mustafa Ugurlu ◽  
Meltem Kilic ◽  
Zuhal Apaydin ◽  
Ali Caykoylu
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Case Report ◽  
Psychotic Symptoms

Primary central nervous system lymphoma: a case report

2011 ◽  
Vol 31 (7) ◽  
pp. 812-812
Author(s):  
Ai-sheng DONG ◽  
Chang-jing ZUO ◽  
Shao-yan WANG ◽  
Ming-jun GAO ◽  
Xiao-hong LI ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Case Report ◽  
Central Nervous System Lymphoma

scholarly journals COVID-19 Vaccination: From Interesting Agent to the Patient

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 120
Author(s):  
Anis Daou
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Gastrointestinal Tract ◽  
Circulatory System ◽  
The Novel ◽  
Lead Compound ◽  
Fda Approval ◽  
The World ◽  
The Central Nervous System ◽  
Novel Coronavirus

The vaccination for the novel Coronavirus (COVID-19) is undergoing its final stages of analysis and testing. It is an impressive feat under the circumstances that we are on the verge of a potential breakthrough vaccination. This will help reduce the stress for millions of people around the globe, helping to restore worldwide normalcy. In this review, the analysis looks into how the new branch of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) came into the forefront of the world like a pandemic. This review will break down the details of what COVID-19 is, the viral family it belongs to and its background of how this family of viruses alters bodily functions by attacking vital human respiratory organs, the circulatory system, the central nervous system and the gastrointestinal tract. This review also looks at the process a new drug analogue undergoes, from (i) being a promising lead compound to (ii) being released into the market, from the drug development and discovery stage right through to FDA approval and aftermarket research. This review also addresses viable reasoning as to why the SARS-CoV-2 vaccine may have taken much less time than normal in order for it to be released for use.

Sign in / Sign up

Export Citation Format

Share Document